KTD-innov
  • L'étude
  • Partenaires
  • FAQ patients
  • Actualités
  • Presse
  • Contact
  • Research
  • Partners
  • Patient's FAQ
  • News
  • Press room
  • Contact us

One more step toward the individualization of treatments

3/14/2019

0 Commentaires

 
Photo
JASN press release "STUDY PROVIDES NEW INSIGHTS ON COMMON POST-TRANSPLANT CONDITION"
File Size: 113 kb
File Type: pdf
Télécharger le fichier

New research conducted by the Paris Translational Research Center for Organ Transplantation team could help clinicians determine which patients will have a disease that usually occurs after a kidney transplant and which are at high risk of transplant failure. The results are published in the prestigious Journal of the American Society of Nephrology (JASN).

Transplant glomerulopathy is a disease associated with the loss of a kidney transplant. There is currently no treatment for this heterogeneous disease.
​This research was able to identify and characterize five distinct patient groups, each with different graft survival outcomes.

This research approach has been translated into a tool accessible to clinicians to assess the risk of graft loss in their patients. This will allow the individualization of patients' treatments according to their group.

Photo
Read the article on JASN: Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival
0 Commentaires

KTD-innov for World Kidney Day on March 14

3/13/2019

0 Commentaires

 
Photo
World Kidney Day, promoted in France by the Kidney Foundation, will take place on March 14. This year, the theme chosen was inequalities in the prevention, early detection and treatment of kidney disease worldwide, under the slogan "Healthy kidneys for everyone, everywhere".

According to the WHO, chronic kidney disease has become a public health issue affecting 10% of the world's population. In France, 3 million people suffer from it and 87,000 of them are treated by dialysis or receive a kidney transplant. For Health Insurance, the cost of this care represents 2% of its total expenses, or €4 billion per year.
​
This is why the Future Investments programme is providing €9 million to support the KTD-innov research project.

Research responds to a real need of patients

Photo
Personnes photo créé par nensuria - fr.freepik.com

​For people with severe chronic kidney disease, a transplant is often the ideal choice because it is less restrictive and less expensive than dialysis. Unfortunately, in France, less than 4,000 people a year are lucky enough to receive a new kidney, and 1,500 people are still on waiting lists.
​
The law of 26 January 2016 on organ donation has made it possible to generalise it but is not enough to sufficiently reduce the list of patients waiting for a kidney transplant. And it happens regularly that patients who have already had a transplant need a new organ a few years after their transplant. That is why the KTD-innov project is looking for a solution to make the graft viable for longer. This solution will allow a personalized medical follow-up of transplanted patients.

​Innovation in research

The KTD-innov project offers a unique approach that combines clinical, biological, immunological and molecular data from the patient. It allows a global vision of the patient and a unique analysis in the world. 
​
Thanks to funding from the French government, KTD-innov will improve knowledge and predict the success of transplants. It is thanks to this innovation that patients can already expect an individualization of their treatment and an increase in the life of their graft by 2022.

Follow the World Day campaign on Twitter

0 Commentaires

10 WINNERS FOR THE UNIVERSITY HOSPITAL HEALTH RESEARCH PROGRAM

9/17/2018

0 Commentaires

 
​Agnès BUZYN, Minister of Solidarity and Health, Frédérique VIDAL, Minister of Higher Education, Research and Innovation, and Louis SCHWEITZER, Commissioner General for Investment, announced at the end of 2017 the allocation of €74.5 million to the 10 winners of this third call for projects "Hospital-University Health Research" (RHU). 
Photo
The call for projects "University Hospital Research in Health" (RHU) of the future investment programme, operated by the National Research Agency, aims to support innovative and large-scale research projects in the health sector. Focused on translational research, HRU projects combine the academic, hospital and business sectors.
​
For this third wave, the international jury examined 52 proposals on the basis of scientific quality and innovation criteria, but also on their potential for medical and socio-economic benefits. It proposed 10 projects for funding covering various therapeutic areas and needs. These projects demonstrate that French excellence in certain future technological fields is becoming a central element for biomedical research. Many projects rely on genomic analysis and big data for the development of diagnostics or treatments. Digital technologies are also present in the selected folders (imaging, connected implants etc.).

The collaborative requirement has helped to strengthen links within the university hospital ecosystem (health institutions, research organizations and universities) not only on one site, but also throughout the country, with many projects bringing together expertise from different regions.

​LIST OF FUNDED PROJECTS

The KTD-innov project, (€8,794,510) aims to prevent the loss of kidney transplants by improving the diagnosis of rejection, predicting the risk of long-term graft loss and response to anti-rejection treatment. KTD-innov has set itself the goal of being the first integrated solution in kidney transplantation that combines molecular medicine and health information technology to provide a precision immune monitoring and diagnostic system for kidney transplantation. The project is led by Prof. Alexandre Loupy (Paris). 

The CiL'LICO project, (€5,976,352) proposes a new approach for the management of a group of rare and serious genetic diseases, ciliopathies that cause deterioration of renal function and lead to end-stage renal failure. The project is led by Professor Stanislas Lyonnet, Director of the Institut Hospitalo-Universitaire Imagine (Paris).

The cirB-RNA project, (€5,910,166) aims to develop a diagnostic test to support the development of curative treatments for hepatitis B, which currently does not exist despite a disease that affects more than 240 million people worldwide. The project is led by Prof. Fabien Zoulim (Lyon).

The EPINOV project, (€5,800,000) aims to improve neurosurgical strategies by introducing an innovative approach to brain modeling. Using epilepsy as a model, the patient's "virtual brain" will allow the epilogenetic zone to be more precisely located, thus guiding an optimal surgical strategy and consequently improving surgical outcomes. The project is led by Prof. Fabrice Bartolomei (Marseille).

The FollowKnee project (€7,900,000) proposes to improve the design, placement and monitoring of implanted prostheses, the number of which has exploded over the past 20 years (+600%), particularly because of their implantation in a younger population often affected by obesity. FollowKnee is led by Prof. Eric Stindel (Brest).

The MyProbe project, (€9,294,317) aims to develop effective tools to identify the high risk of breast cancer relapse and reduce the use of costly and cumbersome additional treatments for patients. MyProbe is led by Professor Fabrice André of the Gustave Roussy Institute (Villejuif).

The PERFUSE project, (€8,000,000) proposes to improve the management of prostate cancer by using high-intensity focused ultrasound (HIFU) ablation to target only the area where the tumour is present. The project is led by Professor Sébastien Crouzier (Lyon).

The PIONeeR project, (€8,502,312) aims to overcome resistance to immunotherapy treatment against the PD-1 checkpoint inhibitor in the treatment of lung carcinoma. The introduction of these new therapies has led to considerable progress, but only 20 to 25% of patients are fully responsive and to date, no predictive factors of efficacy or resistance have been validated. The project is led by Prof. Fabrice Barlesi (Marseille).

The QUID-NASH project, (€8,745,683) aims to revolutionize the management of non-alcoholic hepatic steatosis (NASH) associated with type 2 diabetes by developing a virtual biopsy that will allow patients to be better diagnosed and stratified, but also to facilitate the development of specific NASH treatments. The project is led by Prof. Dominique-Charles Valla (Paris)

The WillAssistHeart project, (€5,600,000) aims to propose new strategies for the diagnosis and treatment of bleeding in patients under mechanical circulatory assistance. The consortium will focus its work on the best-known bleeding risk factor: von Willebrand factor. This factor is sheared when exposed to blood flow disturbances created by the mechanical circulatory support device. The project is led by Professor Sophie Susen (Lille).
0 Commentaires
    Photo

    KTD-INNOV PROJECT

    To elucidate the mechanisms of success or failure of a kidney transplant, KTD-innov collects, centralizes and analyses clinical, biological and immunological data from thousands of kidney transplant patients in France.

    Learn more

    CatEgorIES

    Tout
    Events
    KTD Innov
    KTD-innov
    Patients
    Press Release
    Publication
    Toulouse University Hospital
    University Hospital Of Bordeaux
    University Hospital Of Nantes

    Flux RSS

Plan du site

L'étude
Partenaires
FAQ des patients
Actualités
​
Espace presse
Contact
Mentions légales

Contact

Hôpital Européen Georges Pompidou
56, rue Leblanc
75908 Paris Cedex 15
contact@ktdinnov.fr
Tel. +33 1 53 98 80 00

SOUSCRIRE à notre newsletter


Vous souhaitez recevoir les actualités de KTD-innov par :

Vous pouvez vous désabonner à tout moment en cliquant sur le lien dans le bas de page de nos e-mails. En vous abonnant, vos informations seront transférées à Mailchimp. Voir les pratiques de Mailchimp en matière de confidentialité.

Site map

Research
Partners
Patient's FAQ
News
Press room
Contact us
Legal notice

Contact

​Hôpital Européen Georges Pompidou
56, rue Leblanc
75908 Paris Cedex 15
contact@ktdinnov.fr
Tel. +33 1 53 98 80 00

Subscribe to the Newsletter


You wish to receive KTD-innov newsletter by:

You can unsubscribe at any time by clicking on the link at the bottom of our emails. By subscribing, your information will be transferred to Mailchimp. See Mailchimp's privacy practices.


2018 © Copyright - Labs Explorer pour l'Inserm
  • L'étude
  • Partenaires
  • FAQ patients
  • Actualités
  • Presse
  • Contact
  • Research
  • Partners
  • Patient's FAQ
  • News
  • Press room
  • Contact us